Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Tóm tắt
Từ khóa
Tài liệu tham khảo
Schiller, 2002, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer, N Engl J Med, 346, 92, 10.1056/NEJMoa011954
Azzoli, 2011, 2011 Focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer, J Clin Oncol, 29, 3825, 10.1200/JCO.2010.34.2774
Peters, 2012, Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 23, VII56, 10.1093/annonc/mds226
Buettner, 2013, Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment, J Clin Oncol, 31, 1858, 10.1200/JCO.2012.45.9867
Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med, 350, 2129, 10.1056/NEJMoa040938
Li, 2008, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models, Oncogene, 27, 4702, 10.1038/onc.2008.109
Solca, 2012, Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker, J Pharmacol Exp Ther, 343, 342, 10.1124/jpet.112.197756
Wind, 2013, Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours, Clin Pharmacokinet, 52, 1101, 10.1007/s40262-013-0091-4
Moyer, 1997, Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase, Cancer Res, 57, 4838
Han, 2012, First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung, J Clin Oncol, 30, 1122, 10.1200/JCO.2011.36.8456
Maemondo, 2010, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N Engl J Med, 362, 2380, 10.1056/NEJMoa0909530
Mitsudomi, 2010, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, Lancet Oncol, 11, 121, 10.1016/S1470-2045(09)70364-X
Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699
Rosell, 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, 13, 239, 10.1016/S1470-2045(11)70393-X
Zhou, 2011, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study, Lancet Oncol, 12, 735, 10.1016/S1470-2045(11)70184-X
Sekine, 2008, Emerging ethnic differences in lung cancer therapy, Br J Cancer, 99, 1757, 10.1038/sj.bjc.6604721
Sequist, 2013, Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations, J Clin Oncol, 31, 3327, 10.1200/JCO.2012.44.2806
Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026
Aaronson, 1993, The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J Natl Cancer Inst, 85, 365, 10.1093/jnci/85.5.365
Bergman, 1994, The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials, Eur J Cancer, 30A, 635, 10.1016/0959-8049(94)90535-5
Fayers
Osoba, 1998, Interpreting the significance of changes in health-related quality-of-life scores, J Clin Oncol, 16, 139, 10.1200/JCO.1998.16.1.139
Yang, 2013, Symptom control and quality of life in LUX-Lung 3: a phase iii study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations, J Clin Oncol, 31, 3342, 10.1200/JCO.2012.46.1764
Fukuoka, 2011, Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS), J Clin Oncol, 29, 2866, 10.1200/JCO.2010.33.4235
Yang, 2013, Diarrhea associated with afatinib: an oral ErbB family blocker, Expert Rev Anticancer Ther, 13, 729, 10.1586/era.13.31
Lacouture, 2013, Dermatologic adverse events associated with afatinib: an oral ErbB family blocker, Expert Rev Anticancer Ther, 13, 721, 10.1586/era.13.30
Horiike, 2012, A phase II study of erlotinib as first-line treatment in Japanese advanced NSCLC patients harboring EGFR mutations, Ann Oncol, 23, IX413, 10.1016/S0923-7534(20)33854-0
Douillard, 2013, Efficacy, safety and tolerability results from a phase IV, open-label, single arm study of 1st-line gefitinib in Caucasian patients (PTS) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC), Lung Cancer, 80, S31, 10.1016/S0169-5002(13)70288-5